The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Accelerating the Development and Delivery of

Effective Oncology Treatments

to Patients

 

Cancer Drug Development Forum (CDDF) is a neutral, non–competitive platform

for multi-stakeholder discussions and collaboration in the development of cancer drugs.

 

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive drug development platform working to stimulate the advancement and accessibility of cancer treatment.

Unique Multi-Stakeholder Platform

Patients

Patients are the cornerstone of CDDF’s mission and central to our multi-stakeholder discussions. Patients and advocacy groups are invited to join the CDDF multi-stakeholder community and make their voices heard. Check out collaborative opportunities and grants available to patients.

Industry

The CDDF provides the healthcare industry with unique opportunities to collaborate with diverse stakeholders and take part in open dialogue to accelerate oncology drug development. Discover the CDDF Industry Membership Program and engage with key experts in oncology.

Academia

The CDDF fosters advancement and innovation in cancer research by creating a collaborative platform for academics to share knowledge and expertise with a multi-stakeholder audience. Join CDDF’s discussions on the latest developments and explore opportunities to contribute.

Regulators & HTAs

The CDDF convenes discussions on key topics in oncology, fostering a balanced exchange of perspectives. Regulators and HTA agencies can gain valuable insights and stay informed on emerging trends through our productive dialogue. Explore collaboration opportunities and join our community.

Launch of MSP AG consultation on clinical trials training needs for academia and SMEs | Deadline 11 February 2025 (close of business)

We are pleased to announce the launch of the ACT EU consultation on clinical trials training needs for academia and SMEs. As a reminder, the consultation stems from ACT EU initiative’s Priority Action on clinical trials training aiming to deliver a clinical trials...

Season’s Greetings from the Cancer Drug Development Forum (CDDF)

From all of us at CDDF Team, we wish you a wonderful holiday season filled with peace, joy and health. Happy Holidays and a prosperous New Year!

ICH M15 Guideline on general principles for model-informed drug development

The European Medicines Agency has published for public consultation the ICH M15 Guideline on general principles for model-informed drug development. This guideline provides general recommendations for planning, model evaluation, and documentation of evidence derived...

ICH Guideline for Good Clinical Practice E6(R3) Annex 2

The European Medicines Agency has published for public consultation the ICH Guideline for Good Clinical Practice E6(R3) Annex 2 Good Clinical Practice (GCP), as described in ICH E6(R3) Principles and Annex 1, is applicable across clinical trial types, designs and...

Open consultation on ICH E6 (R3) Annex 2

EMA has opened the public consultation on the draft Annex 2 of ICH E6(R3), following its adoption by EMA’s Committee for Medicinal Products for Human Use (CHMP). As part of the ICH E6 suite, this document addresses Good Clinical Practice (GCP), an international...

Upcoming ACT EU Multi-stakeholder Workshop on ICH E6 R3

As part of the published Accelerating Clinical Trials in the EU (ACT EU) multi-annual workplan 2022-2026 and acknowledging the important role of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Efficiency...

IMPORTANT MESSAGE FROM ACT EU

All clinical trials expected to continue beyond 30 January 2025 must be transitioned to the EU Clinical Trials Regulation (CTR) via the Clinical Trials Information System (CTIS). This date marks the end of a three-year transition period that began when the CTR became...

Multi-stakeholder Interview: Get an Inside Look at the CDDF Multi-Stakeholder Discussion on Innovation and Access in Rare Cancers

The Cancer Drug Development Forum (CDDF) is delighted to share interview clips featuring a diverse group of stakeholders from our recent Multi-Stakeholder Workshop on Innovation and Access in Rare Cancers. Held in Amsterdam on 23-24 September 2024, the meeting...

Key Takeaways from the CDDF Live Webinar on EU Clinical Trial Regulations (Nov 2024)

🔔 📢 The Cancer Drug Development Forum (CDDF) held a live webinar on “EU Clinical Trial Regulations.” on 12 November at 17:00 CET. This webinar featured two lectures given by Dr Tarec Christoffer El-Galaly (Aahrus University, DK) and Stéphanie Kromar (EORTC, BE),...

Strengthened Collaboration between CDDF and Friends of Cancer Research

🔔We are excited to announce that CDDF and  Friends of Cancer Research have formed a strengthened collaboration to accelerate innovative, effective cancer care for patients. By fostering multi-stakeholder collaboration across Europe and globally, we’re committed to...

CDDF Webinar: Bayesian Approaches in Drug Development (July 2024)

The recording of the recent CDDF webinar on Bayesian Approaches in Drug Development is available here. Enjoy the insightful talks from DRob Hemmings (Consilium, UK) followed by an interactive Q&A session.

CDDF & Oncology News

Check out the recent updates within the CDDF and the latest news in the community of cancer research

CDDF Brochure

Access the CDDF Brochure here

 

Join the CDDF community to find ways to accelerate oncology drug development and deliver optimal treatment to cancer patients

COLLABORATION IS THE KEY

TO IMPROVING OUTCOMES

FOR CANCER PATIENTS

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70